Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis’ Exjade gets committee review

Executive Summary

Novartis' oral iron chelator Exjade (deferasirox) will be reviewed for treatment of chronic iron overload during blood transfusions by FDA's Blood Products Advisory Committee on Sept. 29. Panel will likely discuss Exjade's failure to demonstrate non-inferiority to Novartis' current iron overload therapy Desferal in the pivotal study. The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m.[Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit or call 800-627-8171.]...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts